Lexaria Bioscience Corp (LEXX)

$LEXX 90 DAYS STOCK PRICE FORECAST

Stock Price

About the Company

Lexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide.

Exchange

NASDAQ

Website

www.lexariaenergy.com

$1M

Total Revenue

3

Employees

$25M

Market Capitalization

-6.45

Price/Earning ratio

Industry Peers

Name Ticker Market Capitalization (USD M) Revenue (USD M) Price/Book Price/Earning Net Margin (%)
Conversion Labs Inc CVLB 108548 35213 3.74 42.66 7.33
Royalty Pharma plc RPRX 19327 2239 2.87 15.52 43.40
Organon & Co. OGN 8644 7891 -4.46 4.95 22.06
Arvinas Inc ARVN 4342 21 8.14 -26.29 -782.93
Tilray Inc TLRY 3286 513 1.23 -9.74 -71.61
ATAI Life Sciences N.V. ATAI 2545 20 5.35 -11.65 -932.88
Cronos Group Inc CRON 2114 57 1.33 -14.64 -258.59
Usana Health Sciences Inc USNA 1837 1254 4.18 13.23 11.09
Phathom Pharmaceuticals Inc PHAT 1178 7.99 -7.35 None
Fulcrum Therapeutics Inc FULC 925 15 11.21 -12.53 -481.07
Intersect ENT Inc XENT 899 103 21.80 -13.10 -66.55
Phibro Animal Health Corp. PAHC 888 833 3.68 16.16 6.53
Edgewise Therapeutics Inc EWTX 848 2.87 -31.45 None
Pliant Therapeutics Inc PLRX 657 13 2.69 -7.66 -613.56
Cyteir Therapeutics Inc CYT 637 3.42 -22.04 None
Urovant Sciences Ltd UROV 503 -3.65 -3.08 None
Ikena Oncology Inc IKNA 467 10 2.52 -8.53 -551.28
Chromadex Corp CDXC 433 62 10.92 -18.30 -37.51
Rain Therapeutics Inc RAIN 404 413 2.50 -13.27 123.20
Provention Bio Inc PRVB 400 2.68 -3.12 None
Evolus Inc EOLS 321 77 4.24 -2.15 -171.53
Verrica Pharmaceuticals Inc VRCA 316 12 6.41 -8.69 -301.45
Terns Pharmaceuticals Inc TERN 263 1.46 -7.62 None
Adicet Bio Inc ACET 230 9 1.00 -4.09 -603.06
Milestone Pharmaceuticals Inc MIST 222 15 1.25 -7.50 -215.93
Kaleido Biosciences Inc KLDO 222 1 4.94 -2.49 None
LifeMD Inc LFMD 201 64 -28.62 -1.44 -133.55
Kala Pharmaceuticals Inc KALA 187 11 2.42 -1.48 None
Osmotica Pharmaceuticals Plc OSMT 181 190 2.64 -1.95 -47.85
Citius Pharmaceuticals Inc CTXR 177 2.21 -7.70 None
scPharmaceuticals Inc SCPH 162 119 2.38 -5.36 -27.05
Aquestive Therapeutics Inc AQST 146 42 -3.02 -2.27 -152.73
Eton Pharmaceuticals Inc ETON 123 15 6.11 -10.06 -74.52
Odonate Therapeutics Inc ODT 117 1.47 -1.00 None
Eyenovia Inc EYEN 113 6 12.86 -5.77 -324.94
Aerpio Pharmaceuticals Inc ARPO 99 15 2.98 -5.24 -28.77
Opiant Pharmaceuticals Inc OPNT 90 37 2.71 -86.08 -3.06
Natural Alternatives Internati NAII 89 169 1.26 10.07 5.68
VYNE Therapeutics Inc VYNE 72 16 1.08 3.27 -554.66
India Globalization Capital In IGC 67 0 2.39 -7.65 -981.18
Mannatech Inc MTEX 66 158 2.63 10.35 4.22
Acasti Pharma Inc ACST 42 0 1.81 -2.11 -611.47
Shineco Inc TYHT 36 14 1.85 -1.78 -159.60
Assertio Holdings Inc ASRT 33 117 0.45 -0.58 -38.05
Reviva Pharmaceuticals Holding RVPH 30 1.64 -4.74 None
Baudax Bio Inc BXRX 28 1 -11.98 0.84 None
Nabriva Therapeutics Plc NBRV 28 12 0.83 -0.47 -452.55
Bio-Path Holdings Inc BPTH 28 0 1.29 -2.68 18.96
Timber Pharmaceuticals Inc TMBR 26 0 11.39 0.88 -527.55
Trevi Therapeutics Inc TRVI 26 1.67 -0.74 None
Lexaria Bioscience Corp LEXX 25 1 3.49 -6.45 -445.15
Hoth Therapeutics Inc HOTH 22 1.85 -2.29 None
Cyanotech Corp. CYAN 17 34 0.99 13.57 3.83
Sonoma Pharmaceuticals Inc. SNOA 11 17 3.13 -2.04 -31.96

Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment

1d ago, source: YAHOO!Finance

NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: ...

Weak Fundamental Momentum Drags Lexaria Bioscience Corp. (LEXX) Upper

9d ago, source: marketingsentinel

Lexaria Bioscience Corp. (NASDAQ:LEXX) has a beta value of 1.54 and has seen 4.63 million shares traded in the last trading ...

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System

2d ago, source: Yahoo Finance

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of ...

Lexaria Bioscience Corp.: Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

8d ago, source: Finanznachrichten

KELOWNA, BC / ACCESSWIRE / September 9, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces today that Cha ...

Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension

9d ago, source: Associated Press

Positive results using DehydraTECH-CBD support progressing to FDA IND application. KELOWNA, BC / ACCESSWIRE / September 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LE ...

Lexaria Bioscience Corp. To Address Advances In Its Bioavailability Technology DehydraTECH(TM) At Wainwright Life Sciences Conference

4d ago, source: Benzinga.com

Advertiser Disclosure The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the ...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Impressive Blood Pressure Reduction in Hypertension Clinical Trials

4d ago, source: Middle East North Africa Financial Network

Lexaria Bioscience has developed a patented technology that improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing Lexaria's patented ...

Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System

2d ago, source: Stockhouse

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ ...

Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment

1d ago, source: Yahoo Finance

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud ...

Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

8d ago, source: Investing News Network

Lexaria Bioscience Corp. a global innovator in drug delivery platforms announces today that Chairman & CEO Chris Bunka will ...

Your Portfolio